The Beacon Oncology Deals and Companies dataset expansion offers insights into more than 15,500 oncology-related deals and 8,500 companies, supporting smarter, faster strategic decision-making.

Beacon Intelligence has expanded its oncology offering with the launch of Beacon Oncology: Deals and Companies, a new dataset that provides extensive commercial insight into the oncology drug development sector.

Developed in response to the increasing complexity of the commercial oncology market, this latest addition delivers structured and searchable data on over 15,500 oncology-related deals and 8,500 companies, enabling users to make faster, more strategic decisions across R&D, business development, and competitive intelligence functions.

Comprehensive Commercial Intelligence for the Oncology Sector

The Deals and Companies dataset gives subscribers access to curated information on mergers and acquisitions (M&A), licensing agreements, collaborations, partnerships, and funding rounds, alongside detailed company profiles spanning the oncology drug development space.

This dataset expansion is designed to work alongside Beacon’s scientific and clinical trial intelligence to give users a holistic view of the oncology landscape, from research and development through to strategic business activity.

“With this latest dataset, we’re offering our users a new lens through which to view the oncology space—one that brings commercial activity into sharper focus,” said Kieran Pinto, Senior Researcher at Beacon Oncology. “Whether you’re looking to identify potential partners, benchmark licensing deals, or monitor competitors, Beacon Oncology: Deals and Companies delivers the intelligence you need to act quickly and confidently.”

Helping Pharmaceutical and Biotech Professionals Make Smarter Commercial Decisions

With deal-making continuing to play a critical role in oncology innovation, the ability to track and analyse commercial activity in real time is increasingly valuable. Beacon’s new dataset allows users to:

  • Identify acquisition and investment opportunities with access to a broad and deep pool of deal data
  • Evaluate and shortlist potential partners based on company size, therapeutic focus, pipeline stage and more
  • Benchmark licensing and M&A deals to support more informed and competitive negotiations
  • Monitor competitor activity and development strategy in real time through structured, up-to-date data

The dataset expansion covers both public and private deals, with intelligence spanning preclinical research through to commercialisation. All entries are manually curated by Beacon’s in-house analysts to ensure accuracy and relevance.

Built for Commercial, Corporate Development and Business Development Teams

Designed to meet the needs of commercial strategy, business development, and corporate development teams, Beacon Oncology: Deals and Companies enables cross-functional collaboration by aligning market intelligence with R&D strategy.

Its intuitive interface and advanced filtering tools mean users can quickly narrow down to relevant datasets, whether they’re screening for out-licensing partners or comparing deal terms by indication, modality or geography.

The dataset expansion also includes company intelligence pages, providing a single view of a company’s oncology-related activity, partnerships, and pipeline assets. This feature streamlines partner evaluation and helps commercial teams track competitor movement with precision.

Real-Time Intelligence Backed by Beacon’s Proven Platform

The Deals and Companies dataset is built on the same robust platform as Beacon’s scientific and clinical trial databases. That means users benefit from:

  • A unified search experience across all oncology data types
  • Consistent data standards and ontologies for accurate comparisons
  • Regular updates and expert curation to maintain data accuracy
  • A trusted platform already used by hundreds of pharma and biotech teams globally

This launch marks a significant step forward in Beacon’s mission to support smarter, faster oncology drug development by providing end-to-end insight.

Enhancing Decision-Making Across the Oncology Sector

Beacon’s expanded Oncology offering now spans scientific, clinical, and commercial intelligence, offering one of the most comprehensive oncology data ecosystems available. By integrating Deals and Companies with existing datasets, users can:

  • Track how scientific innovations translate into commercial outcomes
  • Identify strategic gaps and opportunities across the market
  • Build more robust development and licensing strategies based on evidence
  • Stay agile in a competitive and rapidly evolving field

Kieran Pinto, Senior Researcher at Beacon Oncology adds: “What sets Beacon apart is our ability to deliver integrated, high-quality datasets that support smarter decisions across the drug development lifecycle. Deals and Companies is the next evolution of that vision, and we’re excited to see how our clients use it to accelerate their commercial strategies.”

Find out more about Beacon Oncology